MALVERN, Pa.--DSG, a provider of electronic data capture (EDC) solutions, has teamed up with a leading-edge pharmaceutical company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.The focus is on developing molecular imaging products that are leading the way to the early detection of human diseases. DSG’s eCaseLink™ EDC supports three current clinical trials for Alzheimer’s disease, Parkinson’s disease and Diabetes. eCaseLink™ supplies real-time capability to review case documents and metrics across all study sites, significantly increasing clinical trial management speed, while reducing study management costs by as much as 30 percent.DSG’s eCaseLink™ allows the pharmaceutical diagnostic and therapeutic company not only to collect and manage their data in real time, but it also gives them the option to add needed functionality as studies progress. They have found that the innovation of the eCaseLink™ product suite, combined with the experience and dedication of the DSG team, is paying immediate and continued dividends for their clinical trial management process.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.